Indeed, the current Bouquet-ENGOT-gyn2 rare ovarian cancers basket trial (ClinicalTrials.gov identifier: NCT04931342) includes an arm for ERBB2/HER2-amplified/mutated cases for treatment with trastuzumab emtansine. Here, ERBB2 is linked to ovarian carcinoma.